Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.9600
+0.1227 (14.65%)
At close: Apr 15, 2026, 4:00 PM EDT
0.9800
+0.0200 (2.08%)
After-hours: Apr 15, 2026, 7:41 PM EDT
RANI Revenue
In the year 2025, Rani Therapeutics Holdings had annual revenue of $1.63M with 58.85% growth. Rani Therapeutics Holdings had revenue of $1.46M in the quarter ending December 31, 2025, with 42.12% growth.
Revenue (ttm)
$1.63M
Revenue Growth
+58.85%
P/S Ratio
58.62
Revenue / Employee
$23,000
Employees
71
Market Cap
95.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.63M | 605.00K | 58.85% |
| Dec 31, 2024 | 1.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.72M | 2.26M | 488.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| Champions Oncology | 57.95M |
| Q32 Bio | 53.74M |
| Pelthos Therapeutics | 16.80M |
| NeurAxis | 3.57M |
| iBio, Inc. | 300.00K |
| aTyr Pharma | 190.00K |
| InflaRx | 34.44K |
RANI News
- 6 days ago - Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - GlobeNewsWire
- 20 days ago - Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 21 days ago - Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - GlobeNewsWire
- 27 days ago - Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - GlobeNewsWire
- 3 months ago - Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - GlobeNewsWire
- 5 months ago - Rani Therapeutics to Participate in the Evercore Healthcare Conference - GlobeNewsWire
- 5 months ago - Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire